Please assess the completion status of the following clinical trial:

Trial Title: Estrogen Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 28 healthy recently postmenopausal women with last menstrual bleeding 12 months at study entry. Women with last menstrual bleeding within 12 months at study entry are those who are peri-menopausal and for whom the drug is FDA approved.~Exclusion Criteria:~* History of hysterectomy, oophorectomy or both~* History of heart disease including cardiac transplantation, heart failure, bypass surgery or percutaneous intervention, and valve disease defined as moderate or severe valve regurgitation or stenosis~* History of bone disease including non-traumatic vertebral fractures on radiography~* Uncontrolled chronic disease (including uncontrolled diabetes defined as a hemoglobin A1C \>8, uncontrolled hypertension defined as a systolic blood pressure \>160 mmHg, awaiting organ transplant)~* Previous or current cancer, excluding basal cell carcinoma~* Previous or current thromboembolic disease~* Previous intolerance of Hormone replacement therapy (HRT) or Oral contraception (OC)~* Current or previous use of HRT within the past 3 months~* Current or recent (\<12 months) substance abuse, including tobacco use~* No drug interactions with HRT~* No racial or ethnic groups will be excluded

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Hormone replacement therapy (Type: ACTIVE_COMPARATOR): Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Inert ingredients by mouth oral daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).